What's hot

View all perspectives
What's Hot
Sleep asleep

Sleep Quality & Psoriatic Arthritis

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Read more →

Ultrasound in PsA

Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Watch video →

Tapering TNFi in nonradiographic AxSpA

Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.

Watch video →

Sunday (Day 2): ACR 22 Daily Recap

ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.

Watch video →

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression

Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)

Watch video →

Deucravacitinib in PsA

Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Watch video →

Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial

Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Watch video →

Best of ACR Day Two in PSA

Watch video →

PET CT Imaging to Define Risk of Progression from PSO to PsA

Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.

Watch video →

ACR22 Daily Recap: Saturday Recap

Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate. 

Watch video →
      RT @uptoTate: Mechanistic target of rapamycin (mTOR) inhibitors may be successful tx of sarcoidosis. Abs 0136 is an inte

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Mechanistic target of rapamycin (mTOR) inhibitors may be successful tx of sarcoidosis. Abs 0136 is an interesting study yielding more questions than answers. #ACR22 @RheumNow https://t.co/0Q260CGw3r https://t.co/LepPOrq7Gv
      RT @RichardPAConway: Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 pa

      Richard Conway RichardPAConway

      3 years 1 month ago
      Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 patients. Sustained remission 78.2% optimised group (vs 66.7%). @rheumnow #ACR22 Abstr#0474 https://t.co/jPRy4RjfJA https://t.co/b1CP8pFwhJ
      RT @synovialjoints: Adding MTX to Pegloticase for 52 wks in gout
      ◦ Improved response rate by 30%
      ◦ Reduced disconti

      Dr. Antoni Chan synovialjoints

      3 years 1 month ago
      Adding MTX to Pegloticase for 52 wks in gout ◦ Improved response rate by 30% ◦ Reduced discontinuation rate by 40% ◦ Greater resolution of tophi by 20% ◦ Similar safety profile in MTX vs non-MTX groups Botson J MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow
      RT @RichardPAConway: Fussner et al. Alpha1-antitrypsin alleles in AAV. Deficiency alleles in 16%. More likely MPA, MPO+.

      Richard Conway RichardPAConway

      3 years 1 month ago
      Fussner et al. Alpha1-antitrypsin alleles in AAV. Deficiency alleles in 16%. More likely MPA, MPO+. Less likely MSK symptoms, granulomatous disease @rheumnow #ACR22 Abstr#0439 https://t.co/Zi7H5UaolS https://t.co/Z04TvugnnE
      RT @DrPetryna: #abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNF

      Olga Petryna DrPetryna

      3 years 1 month ago
      #abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNFi&SEC) respond well to IXE after 12 mo even w/monotherapy:IXE mono (82% pts) change in CDAI from BL to 6 mo -3.6 points& 12 mo -4.9 pts (statistically significant for both) https://t.co/5dRk86A9Xr
      RT @RichardPAConway: de Boysson et al. Incidence GCA across France. Variation in SIR from 7 to 12.Increasing east-west g

      Richard Conway RichardPAConway

      3 years 1 month ago
      de Boysson et al. Incidence GCA across France. Variation in SIR from 7 to 12.Increasing east-west gradient @rheumnow #ACR22 Abstr#0475 https://t.co/XDSSrJcMu5 https://t.co/nlJjcPB3zo
      RT @uptoTate: Abs 0373 details SpA-uveitis more severe in pts w/ smoking hx, axial & peripheral involvement, BASDAI

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Abs 0373 details SpA-uveitis more severe in pts w/ smoking hx, axial & peripheral involvement, BASDAI >4, +HLA-B27, female sex, ^ CRP, hx of B ocular involvement. #ACR22 @RheumNow https://t.co/Fg0v6NVQcI
      RT @RichardPAConway: Mudano et al. explore reasons for COVID-19 vaccine hesitancy. For primary vaccination safety concer

      Richard Conway RichardPAConway

      3 years 1 month ago
      Mudano et al. explore reasons for COVID-19 vaccine hesitancy. For primary vaccination safety concerns most common reason at 52%. For booster, lack of recommendation from physician biggest factor at 39%. @rheumnow #ACR22 Abstr#0083 https://t.co/ISdTmOjIWs https://t.co/Qr47Or2a6v
      RT @RichardPAConway: Sun et al. 44% improved adherence in people with SLE following a 3.8 minute intervention involving

      Richard Conway RichardPAConway

      3 years 1 month ago
      Sun et al. 44% improved adherence in people with SLE following a 3.8 minute intervention involving improved communication @rheumnow #ACR22 Abstr#0063 https://t.co/sFU1FzLUfB https://t.co/9AIOijpI0j
      RT @DrPetryna: #abst0199 #acr22 @rheumnow phase II study: Izokibep -highly potent IL-17A inhibitor w/small molecular s

      Olga Petryna DrPetryna

      3 years 1 month ago
      #abst0199 #acr22 @rheumnow phase II study: Izokibep -highly potent IL-17A inhibitor w/small molecular size designed to overcome limitations of monoclonal Abs: dose-dependent improvement in SF36 & PsAID subdomains, notable improvements in sleep, pain& function. Best in enthesitis https://t.co/VSvhr87PK0
      RT @EBRheum: This might be the greatest honor of my career - thanks for including me @ACRheum!!

      Serious question and I

      Mike Putman EBRheum

      3 years 1 month ago
      This might be the greatest honor of my career - thanks for including me @ACRheum!! Serious question and I’m not sure I want to know the answer Did anyone know the answer? Would be embarrassing 😂🤣😅😳 #ACR22 #KnowledgeBowl #RheumPix @RheumNow https://t.co/GhjXUgCgye
      RT @RichardPAConway: Daikeler et al. No change in incidence permanent vision loss in GCA at 17%. Late presentation (afte

      Richard Conway RichardPAConway

      3 years 1 month ago
      Daikeler et al. No change in incidence permanent vision loss in GCA at 17%. Late presentation (after PVL) and missed diagnosis key areas for improvement. @rheumnow #ACR22 Abstr#0476 https://t.co/CYBHm8CCBv https://t.co/jIvouncdxw
      RT @KDAO2011: Don't repeat the ENA test!
      Retrospect. study 23,438 ENA testing from 19,603 pts: 10% + (mostly Ro52 Ab),

      TheDaoIndex KDAO2011

      3 years 1 month ago
      Don't repeat the ENA test! Retrospect. study 23,438 ENA testing from 19,603 pts: 10% + (mostly Ro52 Ab), 89% neg. 13.4% had ENA test repeated. 96% stable results w/o change Conclusion: ENA results rarely change or yield new diagnosis of AARD #ACR22 @rheumnow abst#0725
      RT @RHEUMarampa: What's the best tx strategy for SLE-induced severe thrombocytopenia?
      This 10-yr retro study by Dr. Cim

      sheila RHEUMarampa

      3 years 1 month ago
      What's the best tx strategy for SLE-induced severe thrombocytopenia? This 10-yr retro study by Dr. Cime-Ake et al. showed that RTX provided longer relapse-free survival (vs. CYC, p=0.040). No difference between IV or oral GCs and AZA or MMF. #ACR22 @RheumNow ABST#368 https://t.co/nzXZMY09jx
      RT @uptoTate: Interim RELIANCE registry data of FMF patients treated with Canakinumab shows efficacy and safety of long-

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Interim RELIANCE registry data of FMF patients treated with Canakinumab shows efficacy and safety of long-term tx including w/ dose adjustments. Abs 0138 #ACR22 @RheumNow https://t.co/ornfXVIw49 https://t.co/eHTIIEhE37

      Podcasts

      • ACR2022 - Day 4 00:14:40
      • Monday ACR 2022 Daily Recap 00:37:20
      • ACR2022 - Day 3.3 00:34:23

      Catch up on Conference Podcasts

      ×